Overview
Very actively managed equity fund. The portfolio is primarily focused on securities from large companies though strategically supplemented by securities from small and medium-sized companies.
The fund manager is given great flexibility to take focused views on the most attractive stocks and exploit the best opportunities, unconstrained by the reference index.
The fund offers investors a broader diversification compared to the index including lower maximum single stock weights (max. 10%) and a more balanced sector allocation.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
The exchange rate risk between CHF and EUR is not hedged.
Benefits
The fund draws on the knowledge of proven investment specialists based in Zurich (Switzerland).
Due to the significant deviation from the reference index, the fund offers the potential to outperform the reference index.
麻豆社's proprietary fundamental valuation approach allows consistent selection of attractive Swiss companies.
Investors benefit from a global investment platform of 麻豆社 Asset Management.
Risks
Features
| Product category |
麻豆社 Equity Funds 麻豆社 Opportunity Equity Funds |
| Product domicile |
Luxembourg
|
| Portfolio management |
麻豆社 Asset Management Switzerland AG, Zurich
|
| Fund management |
麻豆社 Asset Management (Europe) S.A., Luxembourg
|
| Custodian bank |
麻豆社 Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
BNP PARIBAS Securities Services
|
| Day of inception |
September 8, 2015
|
| Currency of account |
CHF
|
| Currency of unit class |
EUR
|
| Close of financial year |
May 31
|
| SFDR Classification |
Art.8
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
1.10% p.a.
|
| Management fee |
0.82% p.a.
|
| Total expense ratio (TER) |
1.07% p.a.
|
| Swing pricing |
yes
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
SPI® (TR)
|
| ISIN |
LU1240788064
|
| Bloomberg Ticker |
麻豆社SEQA LX
|
Performance and Prices
Percentage growth
as of May 27, 2026| EUR(%) | |
| YTD | 5.83 |
| 1M | |
| 3M | |
| 6M | |
| 1Y | 14.42 |
| 2Y | 29.64 |
| 3Y | 32.48 |
| 5Y | 47.55 |
| ø p.a.5Y |
Current data
| Net asset value | 27.05.2026 | EUR 244.79 |
| High - last 12 months | 27.02.2026 | EUR 249.81 |
| Low - last 12 months | 20.06.2025 | EUR 207.42 |
| Assets of the unit class in mn | 27.05.2026 | EUR 1.77 |
| Total product assets in mn | 27.05.2026 | EUR 74.92 |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 30.04.2026 | 13.08% | 13.30% |
| Sharpe Ratio | 30.04.2026 | 0.93 | 0.47 |
| Risk Free Rate | 30.04.2026 | 2.67% | 1.93% |
Structures
By the 10 largest equity positions (in %, as of April 30, 2026)
|
|
|
| Novartis AG | 9.89 |
| Roche Holding AG | 9.81 |
| Nestle SA | 9.80 |
| Zurich Insurance Group AG | 7.75 |
| 麻豆社 Group AG | 5.13 |
| ABB Ltd | 5.04 |
| Swiss Re AG | 4.69 |
| Cie Financiere Richemont SA | 4.39 |
| Givaudan SA | 3.93 |
| Lonza Group AG | 3.23 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
|
| Prospectus |
|
|
| Key Information Document |
|
|
| Past performance |
|
|
| Previous performance scenario |
|
|
|
Document type
|
Document Language
|
|
| Annual report |
|
|
| Semi-annual report |
|
|